Evidence map›Paper›PMID 39944134›Full record

ArticleFrontiers in psychiatry2024

Trace amine-associated receptors (TAARs)2-9 knockout mice exhibit reduced wakefulness and disrupted REM sleep.

Sunmee Park, Jasmine Heu, Gavin Scheldrup, Ryan K Tisdale, Yu Sun, Meghan Haire, Shun-Chieh Ma, Marius C Hoener, Thomas S Kilduff

Abstract read
In one paragraph

Article in Frontiers in psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sunmee ParkCenter for Neuroscience, Biosciences Division, SRI International, Menlo Park, CA, United States.
Jasmine HeuCenter for Neuroscience, Biosciences Division, SRI International, Menlo Park, CA, United States.
Gavin ScheldrupCenter for Neuroscience, Biosciences Division, SRI International, Menlo Park, CA, United States.
Ryan K TisdaleCenter for Neuroscience, Biosciences Division, SRI International, Menlo Park, CA, United States.
Yu SunCenter for Neuroscience, Biosciences Division, SRI International, Menlo Park, CA, United States.
Meghan HaireCenter for Neuroscience, Biosciences Division, SRI International, Menlo Park, CA, United States.
Shun-Chieh MaCenter for Neuroscience, Biosciences Division, SRI International, Menlo Park, CA, United States.
Marius C HoenerNeuroscience and Rare Diseases Discovery & Translational Area, Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.", Basel, Switzerland.
Thomas S KilduffCenter for Neuroscience, Biosciences Division, SRI International, Menlo Park, CA, United States.

Funding

TAAR1-Alzheimers SupplementR01NS103529 · NINDS · SRI INTERNATIONAL · PI KILDUFF, THOMAS S · 2018 to 2022
$3.8M
Nociceptin, NOPR and Sleep/Wake ControlR01NS136808 · NINDS · SRI INTERNATIONAL · PI Thomas S Kilduff · 2024 to 2026
$2.7M
NINDS NIH HHS R01 NS103529NINDS NIH HHS R01 NS136808
6 · The paper itself

Abstract

Introduction: This study aimed to investigate the role of TAAR2-9 in sleep/wake regulation, given TAAR1's known involvement in modulating neurotransmitter release and sleep patterns. Methods: Male TAAR2-9 knockout (KO) and wild-type (WT) mice were compared using baseline sleep/wake patterns, responses to sleep deprivation, effects of TAAR1 agonists, and dopaminergic markers. EEG recordings and tyrosine hydroxylase immunohistochemistry were used for analysis. Results: KO mice exhibited lower delta and theta power and higher gamma power, with fragmented sleep characterized by 16% more NREM sleep during the dark phase and 23% more REM sleep during the light phase compared to WT mice. High doses of the TAAR1 agonist RO5256390 increased wakefulness and reduced NREM sleep, while both RO5256390 and the partial agonist RO5263397 suppressed REM sleep in KO mice. Elevated tyrosine hydroxylase levels in the ventral tegmental area suggested dopaminergic involvement in these altered sleep patterns. Discussion: TAAR2-9 modulates sleep/wake states and interacts with TAAR1. These findings highlight the therapeutic potential of targeting TAARs 2-9 in sleep-related neuropsychiatric disorders. Further research is needed to elucidate their roles.

Indexed as

EEG spectral analysisNREM sleepREM sleepsleep deprivationsleep regulationTAAR2-9Trace amine-associated receptorswakefulness

Identifiers

PMID39944134
PMCPMC11814429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.